Cabaletta Bio (CABA) Competitors $1.27 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.30 +0.03 (+2.36%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CABA vs. MBX, CMPX, DRUG, LFCR, NVCT, IMMP, YMAB, SLRN, HUMA, and PROKShould you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include MBX Biosciences (MBX), Compass Therapeutics (CMPX), Bright Minds Biosciences (DRUG), Lifecore Biomedical (LFCR), Nuvectis Pharma (NVCT), Immutep (IMMP), Y-mAbs Therapeutics (YMAB), Acelyrin (SLRN), Humacyte (HUMA), and ProKidney (PROK). These companies are all part of the "pharmaceutical products" industry. Cabaletta Bio vs. MBX Biosciences Compass Therapeutics Bright Minds Biosciences Lifecore Biomedical Nuvectis Pharma Immutep Y-mAbs Therapeutics Acelyrin Humacyte ProKidney Cabaletta Bio (NASDAQ:CABA) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Does the MarketBeat Community prefer CABA or MBX? Cabaletta Bio received 88 more outperform votes than MBX Biosciences when rated by MarketBeat users. However, 100.00% of users gave MBX Biosciences an outperform vote while only 72.52% of users gave Cabaletta Bio an outperform vote. CompanyUnderperformOutperformCabaletta BioOutperform Votes9572.52% Underperform Votes3627.48% MBX BiosciencesOutperform Votes7100.00% Underperform VotesNo Votes Is CABA or MBX more profitable? MBX Biosciences' return on equity of 0.00% beat Cabaletta Bio's return on equity.Company Net Margins Return on Equity Return on Assets Cabaletta BioN/A -50.10% -45.49% MBX Biosciences N/A N/A N/A Do analysts prefer CABA or MBX? Cabaletta Bio presently has a consensus target price of $21.00, suggesting a potential upside of 1,534.24%. MBX Biosciences has a consensus target price of $37.50, suggesting a potential upside of 297.58%. Given Cabaletta Bio's higher probable upside, equities analysts plainly believe Cabaletta Bio is more favorable than MBX Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor CABA or MBX? In the previous week, MBX Biosciences had 2 more articles in the media than Cabaletta Bio. MarketBeat recorded 2 mentions for MBX Biosciences and 0 mentions for Cabaletta Bio. MBX Biosciences' average media sentiment score of 0.36 beat Cabaletta Bio's score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Cabaletta Bio Neutral MBX Biosciences Neutral Which has better earnings and valuation, CABA or MBX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCabaletta BioN/AN/A-$67.68M-$2.34-0.55MBX BiosciencesN/AN/AN/AN/AN/A SummaryMBX Biosciences beats Cabaletta Bio on 5 of the 9 factors compared between the two stocks. Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CABA vs. The Competition Export to ExcelMetricCabaletta BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.21M$2.92B$5.39B$7.74BDividend YieldN/A1.91%5.44%4.32%P/E Ratio-0.6029.1422.0918.24Price / SalesN/A479.71397.71104.73Price / CashN/A168.6838.2034.62Price / Book0.233.026.724.19Net Income-$67.68M-$72.17M$3.21B$247.59M7 Day Performance16.82%9.78%5.42%5.97%1 Month Performance-22.59%-5.90%-4.67%-3.59%1 Year Performance-89.45%-19.36%17.72%4.84% Cabaletta Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CABACabaletta Bio1.8652 of 5 stars$1.27flat$21.00+1,553.5%-90.2%$64.44MN/A-0.5950Gap UpMBXMBX Biosciences2.1059 of 5 stars$6.93-6.5%$37.50+441.1%N/A$231.63MN/A0.0036CMPXCompass Therapeutics3.4051 of 5 stars$1.66-2.4%$13.38+708.2%+43.2%$228.86M$850,000.00-4.4720Analyst ForecastDRUGBright Minds Biosciences3.4338 of 5 stars$32.28+12.0%$84.33+161.3%+2,966.1%$227.38MN/A-189.87N/APositive NewsLFCRLifecore Biomedical1.8301 of 5 stars$6.14+5.5%$8.00+30.3%-2.5%$227.33M$130.86M-10.96690NVCTNuvectis Pharma2.0204 of 5 stars$9.46+13.8%$15.67+65.6%+63.3%$221.29MN/A-8.168News CoveragePositive NewsGap UpIMMPImmutep1.0481 of 5 stars$1.52+4.1%$8.50+459.2%-35.1%$221.25M$5.14M0.002,021News CoveragePositive NewsYMABY-mAbs Therapeutics3.6011 of 5 stars$4.86+0.6%$18.30+276.5%-73.0%$219.76M$87.69M-9.00150Analyst DowngradeAnalyst RevisionNews CoveragePositive NewsSLRNAcelyrin3.4108 of 5 stars$2.17-2.7%$9.60+342.4%-52.5%$218.97MN/A-0.88135HUMAHumacyte2.261 of 5 stars$1.49-2.9%$13.71+823.5%-61.3%$215.09M$1.57M-1.11150Analyst RevisionPROKProKidney2.3588 of 5 stars$0.73+0.4%$5.00+581.0%-63.5%$214.90M$76,000.00-1.333Insider TradePositive News Related Companies and Tools Related Companies MBX Competitors CMPX Competitors DRUG Competitors LFCR Competitors NVCT Competitors IMMP Competitors YMAB Competitors SLRN Competitors HUMA Competitors PROK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CABA) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
